Cns Pharmaceuticals Stock News

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. CNS Pharmaceuticals (NASDAQ: CNSP ), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today released a video to shareholders that reiterates its operational and clinical progress for lead product candidate, Berubicin , and addresses recent share price activity. “The divergence that exists between our operational strength and share price is top of mind for myself and the whole team at CNS Pharmaceuticals. As a shareholder of CNS Pharma, I share in the frustrations as it pertains to the share price and fluctuation in the market – both of which are things out of our control. However, as the CEO, what I do have control over is executing on the day-to-day operations, which I want to reiterate and emphasize, have simply never been stronger,” said John Climaco, CEO of CNS Pharmaceuticals. “We continue to enroll patients around the world in our potentially pivotal study of Berubicin in the treatment of adult GBM.

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) with the stream of 6.22% also noticed, India RealNetworks, Inc. (NASDAQ:RNWK) encountered a rapid change of 6.55% in the last hour of Wednesday’s trading session. CNS … The post Bright Trending Stock: CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), RealNetworks, Inc. (NASDAQ:RNWK) appeared first on Stocks Equity .

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. CNS Pharmaceuticals recently received approval from swissethics for a pivotal Berubicin and GBM clinical trial The company also participated in the H.C. Wainwright BioConnect Conference earlier in January The five-year survival rate for GBM is only 6.8%, with the average patient population surviving 12 to 18 months after diagnosis CNS Pharmaceuticals (NASDAQ: CNSP ), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, recently participated in the Virtual Investor 2022 Top Picks Conference. During the event, CEO John Climaco provided a corporate presentation and then participated in a moderated questions and answer session. In addition to being moderated, investors and interested parties were given the opportunity … Full story available on Benzinga.

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. CNS Pharmaceuticals (NASDAQ: CNSP ), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today reported its financial results for the year ended Dec. 31, 2021. The company also provided a clinical update of its anti-cancer drug candidates currently in development for the treatment of primary and metastatic brain and CNS cancer. “Operationally 2021 was a terrific year for the company as we established the global framework for building and expanding our potentially pivotal clinical study of Berubicin for the treatment of GBM. Our priority remains focused on advancing Berubicin to bring a meaningful treatment to patients, families and clinicians, who currently have extremely limited and often ineffective treatment options. I am continually impressed by the speed and efficiency with which our small team has executed our Berubicin trial.

HOUSTON, March 3, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its…

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. CNS Pharmaceuticals (NASDAQ: CNSP ) recently received approval from swissethics, the umbrella organization of the cantonal Ethics Committees in Switzerland. The first from a European Ethics Committee, the approval marks a significant milestone for the company as it journeys toward its potentially pivotal study of Berubicin, an anthracycline, for the treatment of Glioblastoma Multiforme (GBM). The approval also partly fulfills CNSs goal of seeing Berubicin approved for the potential treatment of GBM globally. GBM is one of the most aggressive, deadly and treatment-resistant cancers that form in the brain. So far, the company has selected tens of clinical sites across the United States, Spain, France, Italy, and Switzerland. In addition, CNS has already dosed the first patients in its Berubicin clinical development program, an article discussing the study reads.

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Here is how CNS Pharmaceuticals, Inc. (CNSP) and Celyad SA (CYAD) have performed compared to their sector so far this year.

HOUSTON, Jan. 20, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary an

HOUSTON, Jan. 7, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and

CNS Pharmaceuticals (CNSP) trades 19.6% down premarket after it entered into securities purchase agreements with several institutional and accredited investors for issuing 12.1M shares in

HOUSTON , Jan. 6, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP ) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system (CNS), announced today that it has entered into securities purchase agreements with several institutional and accredited investors to issue, in a private placement priced at-the-market under Nasdaq rules, 12,105,264 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 12,105,264 shares of common stock, at a purchase price of $0.95 per share of common stock (or pre-funded warrant) and associated warrant, for expected gross proceeds to CNS of approximately $11.5 million , before deducting placement agent fees and other offering expenses payable by the Company. The warrants will have an exercise price of $0.82 per share of common stock, will be exercisable immediately upon issuance for a period of five years from the date of issuance.

Cns Pharmaceuticals Inc (CNSP) shares closed today 31.4% higher than it did at the end of yesterday. The stock is currently up 13.8% year-to-date, down 54.8% over the past 12 months, and down 82.5% over the past five years. Today, the Dow Jones Industrial Average fell 1.0%, and the S&P 500 fell 1.9%. Trading Activity Shares traded as high as $0.81 and as low as $0.69 this week.Shares closed 76.5% below its 52-week high and 51.6% above its 52-week low.Trading volume this week was 21.7% lower than the 10-day average and 4.1% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 1065.6% The company's stock price performance over the past 12 months lags the peer average by 83.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Check these penny stocks out today following big moves The post These Penny Stocks Exploded Today, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.